NCT05453396

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: TERMINATED

Phase: PHASE2

Sponsor: University of Washington

Condition: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma

Signal summary

Public flags

Status signal: Registry Stop Signal

Timeline signals: None

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal | complex_intervention_signal

Stopped reason

Context when available

The trial closed early due to slow accrual.